Respiratory Syncytial Virus (RSV) is a pathogenic virus belonging to the Paramyxoviridae family, known for causing respiratory tract infections in humans, particularly in infants, young children, and the elderly. The virus is characterized by its negative-sense, single-stranded RNA genome, which encodes for several structural and non-structural proteins essential for viral replication and propagation. Among these proteins, the fusion (F) protein plays a critical role in viral entry and infection. The F protein is responsible for mediating the fusion of the viral envelope with the host cell membrane, facilitating the entry of viral genetic material into the host cell cytoplasm. Additionally, RSV possesses attachment (G) and fusion (F) glycoproteins that facilitate viral attachment to host cells and subsequent membrane fusion, respectively. Through these interactions, RSV gains entry into host cells, initiating viral replication and propagation within the respiratory epithelium.
Activation of Respiratory Syncytial Virus (RSV) involves a complex interplay between viral glycoproteins and host cell receptors and signaling pathways. The initial step of activation occurs when the viral attachment (G) protein interacts with specific cellular receptors on the surface of respiratory epithelial cells, facilitating viral attachment and entry. Subsequently, the fusion (F) protein undergoes conformational changes triggered by interactions with host cell receptors, leading to the exposure of fusion peptides and the initiation of membrane fusion. This fusion process allows the viral genome to enter the host cell cytoplasm, where it can initiate viral replication and gene expression. Furthermore, activation of intracellular signaling pathways, such as those involving calcium influx and protein kinase activation, may also contribute to viral replication and propagation by facilitating viral protein synthesis and assembly. Overall, the activation of RSV involves a series of coordinated events that enable viral entry, replication, and spread within the respiratory tract, ultimately leading to respiratory tract infections.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $91.00 $139.00 $374.00 | 36 | |
A corticosteroid that can suppress immune responses, potentially allowing for increased RSV replication. | ||||||
Prednisolone | 50-24-8 | sc-205815 sc-205815A | 1 g 5 g | $84.00 $253.00 | 2 | |
Similar to dexamethasone, this corticosteroid might suppress the immune system, potentially facilitating RSV replication. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
An immunosuppressant that could potentially increase susceptibility to RSV infection. | ||||||
FK-506 | 104987-11-3 | sc-24649 sc-24649A | 5 mg 10 mg | $78.00 $151.00 | 9 | |
Another immunosuppressant that might enhance RSV replication by reducing host immune response. | ||||||
Mycophenolate mofetil | 128794-94-5 | sc-200971 sc-200971A | 20 mg 100 mg | $37.00 $109.00 | 1 | |
Immunosuppressant, which may allow for increased viral propagation in the host. | ||||||
Azathioprine | 446-86-6 | sc-210853D sc-210853 sc-210853A sc-210853B sc-210853C | 500 mg 1 g 2 g 5 g 10 g | $203.00 $176.00 $349.00 $505.00 $704.00 | 1 | |
As an immunosuppressive agent, it could potentially facilitate RSV replication. | ||||||
Hydrocortisone | 50-23-7 | sc-300810 | 5 g | $102.00 | 6 | |
Corticosteroid that may suppress immune response, potentially aiding in RSV replication. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $94.00 $213.00 | 33 | |
Immunosuppressant that might inadvertently facilitate RSV replication. | ||||||